MRSA

Linyu Ding1, Xiaoliu Liang1,2, Jiaxin Ma1,3

  • 1State Key Laboratory of Infectious Disease Vaccine Development, Xiang'an Biomedicine Laboratory, National Innovation Platform for Industry-Education Integration in Vaccine Research, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, 361102, P. R. China.

概括

这项研究介绍了AMV@NanoCip,这是一种针对耐甲基金色葡萄球菌 (MRSA) 感染的新型纳米药物. 这种创新方法结合了有针对性的治疗与超声波刺激,提高了对呼吸道感染的抗菌疗效.